- Home
- RLAY vs NDMO Comparison
RLAY vs NDMO Comparison
Compare RLAY & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- NDMO
- Stock Information
- Founded
- RLAY 2015
- NDMO 2019
- Country
- RLAY United States
- NDMO United States
- Employees
- RLAY N/A
- NDMO N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- NDMO Trusts Except Educational Religious and Charitable
- Sector
- RLAY Health Care
- NDMO Finance
- Exchange
- RLAY Nasdaq
- NDMO Nasdaq
- Market Cap
- RLAY 619.0M
- NDMO 620.6M
- IPO Year
- RLAY 2020
- NDMO N/A
- Fundamental
- Price
- RLAY $3.99
- NDMO $10.39
- Analyst Decision
- RLAY Strong Buy
- NDMO
- Analyst Count
- RLAY 13
- NDMO 0
- Target Price
- RLAY $18.00
- NDMO N/A
- AVG Volume (30 Days)
- RLAY 1.2M
- NDMO 218.6K
- Earning Date
- RLAY 11-05-2025
- NDMO 01-01-0001
- Dividend Yield
- RLAY N/A
- NDMO 6.75%
- EPS Growth
- RLAY N/A
- NDMO N/A
- EPS
- RLAY N/A
- NDMO N/A
- Revenue
- RLAY $8,355,000.00
- NDMO N/A
- Revenue This Year
- RLAY $31.55
- NDMO N/A
- Revenue Next Year
- RLAY N/A
- NDMO N/A
- P/E Ratio
- RLAY N/A
- NDMO N/A
- Revenue Growth
- RLAY N/A
- NDMO N/A
- 52 Week Low
- RLAY $1.78
- NDMO $8.99
- 52 Week High
- RLAY $8.32
- NDMO $11.24
- Technical
- Relative Strength Index (RSI)
- RLAY 58.70
- NDMO 72.17
- Support Level
- RLAY $3.87
- NDMO $9.72
- Resistance Level
- RLAY $4.20
- NDMO $9.98
- Average True Range (ATR)
- RLAY 0.21
- NDMO 0.11
- MACD
- RLAY 0.03
- NDMO 0.07
- Stochastic Oscillator
- RLAY 66.87
- NDMO 88.55
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.